CLOs on the Move

Managed Health Care Associates

www.mhainc.com

 
Managed Health Care Associates, Inc. (MHA) is not only the country`s largest alternate site GPO, but also has established itself as a leading health care services and technology company. This evolution reflects our commitment to stay abreast of changes in the alternate site health care market and invest in innovative solutions, technologies and services for our members including long-term care pharmacies, infusion pharmacies, specialty pharmacies, home medical equipment providers and assisted living and skilled nursing facilities.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.mhainc.com
  • 25-A Vreeland Road, Suite 200 P.O. Box 789
    Florham Park, NJ USA 07932
  • Phone: 973.966.9200

Executives

Name Title Contact Details
Christine Carver
Vice President and Deputy General Counsel Profile
Justin Kim
Associate General Counsel Profile

Similar Companies

Frontier Scientific

Frontier Scientific is a Logan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

WN Pharmaceuticals

WN Pharmaceuticals Ltd is a Coquitlam, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Frontida BioPharm

Frontida BioPharm is a Minority-Owned Contract Development & Manufacturing Organization. We work collaboratively with our clients to bring new and improved products to the pharmaceutical market. By leveraging our team`s vast knowledge and experience we are able to improve the success of our client`s business and product development efforts. Frontida was launched by founding management team members of Frontage Laboratories. Having 15 years of success in the business Frontage remains a thriving CRO that has become a full service R&D organization located in PA, NJ, and China. With strong record of FDA compliance and quality service to global pharmaceutical and biotechnology companies, the Frontage team easily founded Frontida. While Frontage and Frontida remain affiliates, they are separate business entities.

La Jolla Pharmaceutical

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has several product candidates in development. LJPC-501 is La Jolla`s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension. LJPC-401 is La Jolla`s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is our next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.